Integra LifeSciences Stock Rises On Street-Beating Q3 Earnings, Raises FY21 EPS Guidance
Integra LifeSciences Holdings Corporation (NASDAQ:IART) shares got a boost as Q3 adjusted EPS of $0.86 topped the consensus forecast of $0.72.…
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
Here's a roundup of top developments in the biotech space over the last 24 hours:
Integra Lifesciences Q3 EPS $0.86 Beats $0.72 Estimate, Sales $386.86M Beat $384.58M Estimate
Integra Lifesciences (NASDAQ:IART) reported quarterly earnings of $0.86 per share which beat the analyst consensus estimate of $0.72 by 19.44 percent. This is a 7.5 percent increase over earnings of $0.80 per share from
Earnings Scheduled For November 2, 2021
Companies Reporting Before The Bell
• Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per share on revenue of $1.86 billion.
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.
5 Stocks Insiders Are Selling
When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to go short on the stock. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision.
BTIG Downgrades Integra Lifesciences to Neutral
BTIG analyst Ryan Zimmerman downgrades Integra Lifesciences (NASDAQ:IART) from Buy to Neutral.
Notable Integra Lifesciences Insider Trades $11.46 Million In Company Stock
Peter Arduini, President And Ceo at Integra Lifesciences (NASDAQ:IART), made a large buy and sell of company shares on September 3, according to a new SEC filing.
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer’s Conference, IPOs and More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start to the pharma reporting season.